Xencor Q1 2025 Earnings Report

Xencor EPS Results

• Actual EPS: -$0.66
• Consensus EPS: -$0.60
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: -$1.11

Xencor Revenue Results

• Actual Revenue: $32.73 million
• Expected Revenue: $23.44 million
• Beat/Miss: Beat by +$9.29 million
• YoY Revenue Growth: +104.60%

Xencor Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, May 7, 2025
• Conference Call Time: 4:00PM ET

Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies and cytokine therapeutics for cancer, autoimmune diseases and other serious medical conditions. The company’s research is based largely on its XmAb technology platform, which is designed to modify antibody structures to improve immune-system activity, extend drug half-life or enable the simultaneous targeting of multiple biological pathways.

Xencor’s pipeline includes investigational therapies intended to engage immune cells, regulate immune responses and target tumor-associated proteins. Its programs have included bispecific antibodies and cytokine-based medicines for oncology and immunology applications. Xencor has also entered into collaborations and licensing arrangements with larger pharmaceutical companies to develop and commercialize medicines incorporating its antibody-engineering technologies. Tafasitamab, marketed as Monjuvi in the United States, is one example of a commercial product developed using Xencor’s technology.

Founded in 1997 and headquartered in Monrovia, California, Xencor conducts research and development primarily in the United States while working with commercial and development partners serving international markets. John Desjarlais, Ph.D., serves as the company’s president and chief executive officer. Xencor’s business model combines internal drug development with partnerships intended to broaden the application of its XmAb platform.